S&P Capital IQ Initiates Coverage on Integrity Applications, Inc. in Standard & Poor's Factual Stock Reports
NEW YORK, July 3, 2013 /PRNewswire/ -- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Integrity Applications, Inc.
Integrity Applications, Inc. (OTCQB:IGAP), in the development stage as of December 31, 2012, is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company operates primarily through its wholly owned subsidiary, A.D. Integrity Applications, Ltd., an Israeli corporation, which was founded in 2001.
The company has developed a non-invasive blood glucose monitor, the GlucoTrack® model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger-stick devices. The GlucoTrack DF-F utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood.
Integrity announced on June 4, 2013, that it has received CE Mark approval for its GlucoTrack DF-F non-invasive blood glucose measurement device. Receipt of the CE Mark allows Integrity Applications to market and sell the GlucoTrack DF-F glucose monitoring device in European Union (EU) member countries that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety (although certain EU member countries may request or require additional performance and/or safety data from time to time, on a case-by-case basis). The CE mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU.
Integrity Applications has disclosed that it intends to enter into agreements with various third parties for the preparation and manufacture of its products as it does not have commercial manufacturing facilities and does not intend to build commercial manufacturing facilities of its own in the foreseeable future. Integrity builds prototypes of GlucoTrack devices for testing, including for limited use in clinical testing, using parts manufactured by subcontractors and assembles them in the company's Ashkelon, Israel offices.
In March 2013, Integrity Applications raised gross proceeds of approximately $6.3 million in an offering of 6,300 units, each of which consisted of one share of the company's newly designated Series A 5% Convertible Preferred stock with a conversion price of $5.80 per share, and a warrant to purchase, at an exercise price of $6.96 per share, up to 100% of the shares of common stock issuable upon conversion of such share of preferred stock.
Standard & Poor's Factual Stock Report coverage on Integrity applications, Inc. will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Additional information regarding Integrity Applications is available on its website, located at www.integrity-app.com
About Standard & Poor's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.
Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: www.spcapitaliq.com.
Integrity Applications, Inc.
D. Rafael Toledano, Director of Investor Relations
+1 (888) 224-9446
+972 (8) 675-7878
S&P Capital IQ
Richard Albanese, 212-438-3647
Michael Privitera, 212-438-6679
SOURCE S&P Capital IQ
More by this Source
S&P Capital IQ Initiates Coverage on BioCorRx Inc. in S&P Capital IQ Factual Stock Reports
Apr 03, 2014, 10:37 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.